Trump’s psychedelic order tests review norms Atypical policymaking process raises concerns about rigor, precedent and politicization of regulatory decisions President Donald Trump’s executive order on psychedelics could accelerate the path to market for a... See more
Makary’s embrace of ideology, conspiracies puts FDA at risk: A Perspective Because the FDA commissioner is making regulatory decisions, his views about scientific evidence are concerning FDA Commissioner Marty Makary’s endorsement of debunked conspiracy t... See more
America welcomed Elias Zerhouni — today the door would be closed
The former NIH director warns anti-immigrant policies, assaults on universities make it impossible for others to follow his path
Elias Zerhouni personifies the American dream. He arrived in ... See more
Tidmarsh signals higher bar for accelerated approvals but faster trial starts
CDER director says FDA is re-evaluating cancer endpoints and moving to speed clinical trial regulation, including IND process
With the DOGE wrecking ball retired and the dust be... See more
Tidmarsh signals higher bar for accelerated approvals but faster trial starts
CDER director says FDA is re-evaluating cancer endpoints and moving to speed clinical trial regulation, including IND process
With the DOGE wrecking ball retired and the dust be... See more
